PBYI - Puma Biotech Struggles To Find Its Footing In Crowded Oncology Space
- Puma's sales fell 17% last year and the company continued burning cash.
- Four years into the launch of Nerlynx, market penetration remains below expectations.
- Recent trial updates provide little hope of changing the narrative around Nerlynx.
For further details see:
Puma Biotech Struggles To Find Its Footing In Crowded Oncology Space